The time of day that intravenous ICI therapy is administered is unlikely to significantly affect OS in patients with non-small cell #lungcancer.
https://bit.ly/48s4AQu
#NSCLC #ELCC26
0
0
0
0
Hashtag
#ELCC26
Advertisement · 728 × 90
Prof. Nicolas Girard joins COR2ED at the European Lung Cancer Congress, #ELCC26 , to share his highlights on oncogene-addicted NSCLC data from key trials, like Beamion LUNG-1, SOHO-01, OptiTROP-Lung03, and more. @nicogirardcurie
Visit the COR2ED website
buff.ly/m7V2NCu
0
0
0
0
📣 All #ELCC26 sessions with speaker permission are now online for registered delegates & ESMO members on #OncologyPRO
Watch on demand and stay at the forefront of #ThoracicOncology
🔗 https://ow.ly/hsgC50YB30R
0
2
0
0
🫁Varying outcomes were observed following treatment with cemiplimab-rwlc plus chemotherapy in molecularly defined subsets of patients with nonsquamous NSCLC @myesmo.bsky.social #lscm #NSCLC #oncology #ELCC26
www.onclive.com/view/empower...
1
0
0
0
🫁Now that #ELCC26 is Over, we've got you covered!
The latest OncoAlert Special Edition Newsletter is out — our picks of the top trials:
REGISTERE HERE 👉 oncoalert.m-pages.com/nhMpwe/oncoa... or www.OncoAlert360.com
Written for oncologists, by oncologists. 👉 Register at www.OncoAlert360.com
0
0
0
0
Joachim Aerts discusses whether the benefits of low-dose computed tomography (#LDCT) can be extended to never-smokers, highlighting data from the Chinese Lung-Care Project presented at #ELCC26. Read more in the #ESMODailyReporter ➡️ https://ow.ly/U5j050YzNuM
0
1
0
0
📌@mdcurioni.bsky.social discusses the challenges of overcoming acquired resistance to #immunotherapy in #NSCLC, highlighting some positive and negative trial data from #ELCC26. Learn more in the #ESMODailyReporter 👉 https://ow.ly/f7WB50YA1b0
0
0
0
0
WATCH: Fred R. Hirsch, MD, PhD, of @mountsinainyc.bsky.social discusses research validating an AI-assisted PD-L1 scoring algorithm against original Blueprint study data in lung cancer. #ELCC26 #lcsm #lungcancer #AI
www.onclive.com/view/dr-hirs...
0
1
0
0
WATCH: Nicolas Girard, MD, PhD, of @institutcurie.bsky.social discusses updated data from the phase 2 PALOMA-2 trial that were presented at the 2026 European Lung Cancer Congress. #ELCC26 #ELCC2026 #lcsm #lungcancer
www.onclive.com/view/dr-gira...
1
0
0
0
💫
Best of #ELCC26
#gotistobart — novel pH-sensitive anti-CTLA-4 antibody that selectively depletes intratumoral Tregs — vs docetaxel in metastatic sqNSCLC after anti-PD-(L)1 + platinum:
→ Median OS: not reached vs 10 months
12mOS: 63vs30% (HR 0.46)
→ ORR: 20% vs 4.8%
→ Manageable safety profile
1
0
1
0
#ELCC26: Optimising #CancerTreatment is essential. In the #ESMODailyReporter,Sanjay Popat highlights strategies to enhance treatment effects, overcome resistance and improve supportive care.
Read the editorial: https://ow.ly/663V50YzMUm
1
0
0
0
0
0
0
0
#ELCC26: Improved overall survival was observed with gotistobart, a novel anti-CTLA-4 antibody, versus docetaxel in stage 1 of the PRESERVE-003 trial in patients with squamous #NSCLC who progressed on anti-PD-(L)1 therapy.
#ESMODailyReporter 📌 https://ow.ly/TU2Z50YzKVC
1
0
0
0
The #OncoAlertColloquium 2026 Thoracic Malignancies🚨 #ELCC26
WATCH HERE👉 vimeo.com/1160841460?s...
Presentation by Dr. Biagio Ricciuti🇺🇸 : Year in Review Early #NSCLC
2
1
0
0
#ELCC26: Non-inferiority for overall survival was demonstrated with late versus early IV #immunotherapy administration in the ETOP-Roche i-TiMES meta-analysis of 8 trials in ##LungCancer. Read more in the #ESMODailyReporter 📌 https://ow.ly/bmty50YzJjT
0
0
0
0
A Great Start to Day 3 of #ELCC26
Kudos to the @myESMO team on another amazing meeting and our gratitude to our colleagues keeping colleagues worldwide up to date
✅8.3 million impressions
0
0
0
0
🫁Calderasib showed strong efficacy, with ORRs up to 72% in combination with pembrolizumab in patients with KRAS G12C–mutant metastatic NSCLC. @myesmo.bsky.social
#ELCC26 #lcsm
www.onclive.com/view/caldera...
0
0
0
0
🫁Calderasib showed strong efficacy, with ORRs up to 72% in combination with pembrolizumab in patients with KRAS G12C–mutant metastatic NSCLC. @myESMO
#ELCC26 #lcsm
www.onclive.com/view/caldera...
1
0
0
0
Adagrasib shows differentiated activity in KRAS G12C–mutant NSCLC 🔬
In ADEPPT, elderly patients with ECOG 0-1 saw meaningful, durable responses, while those with ECOG 2 had limited benefit despite some QOL gains.
Learn more: www.onclive.com/view/ecog-pe...
@myesmo.bsky.social #ELCC26 #lcsm
0
0
0
0
#ELCC26: Results from ETOP ADEPPT demonstrate the benefits of adagrasib in older patients but caution is needed in patients with poor performance status.
Read more of the latest insights in KRAS G12C-mutated #NSCLC in the #ESMODailyReporter ➡️ https://ow.ly/TXC050YzeZ0
0
0
0
0
The #OncoAlertColloquium 2026 Thoracic Malignancies🚨 #ELCC26
Presentation by Dr. Gilberto Lopes🇺🇸 : Year in Review Early #NSCLC
WATCH NOW, NO REGISTRATION👉 buff.ly/hqSd5tp
Practice-changing research in 2025 in early NSCLC 🚀
0
0
0
0
In an Opinion piece in the #ESMODailyReporter, Umberto Malapelle explains how presentations at #ELCC26 have sought to incorporate multimodal insights into early detection, progression prediction and rehabilitation: https://ow.ly/Qu2B50Yz7Ca
0
0
0
0
Setidegrasib yielded antitumor activity with a tolerable safety profile in KRAS G12D-mutated NSCLC. @myesmo.bsky.social #ELCC26 #ELCC2026 #lcsm #oncology
www.onclive.com/view/setideg...
0
0
0
0
Osimertinib plus chemotherapy prolonged PFS vs osimertinib alone in patients with advanced NSCLC harboring concurrent EGFR and TP53 mutations.
@myesmo.bsky.social
#ELCC26 #ELCC2026 #lcsm #oncology
www.onclive.com/view/osimert...
0
0
0
0
Frontline iza-bren in combination with serplulimab was associated with a tolerable and manageable safety profile and elicited responses in ES-SCLC. @myesmo.bsky.social #ELCC26 #ELCC2026 #lcsm #oncology
www.onclive.com/view/first-l...
0
0
0
0
Interesting to see Ben Solomon speak about early immune-based approaches in ALK+ lung cancer at #ELCC26.
Alongside TKIs, researchers are also looking at whether the immune system could be better engaged in ALK+ #lungcancer, including through ALK vaccines and ALK-specific T cell approaches. #LCSM
5
0
0
0
A figure showing KRAS G12D protein degradation.
Presented at #ELCC26:
In a phase 1 trial of setidegrasib, a KRAS G12D degrader, 42% of patients had adverse events of grade 3 or higher; 36% of patients with NSCLC and 24% of those with pancreatic cancer had a response. Full trial results: nej.md/3O0pWNY
@myesmo.bsky.social
4
1
0
0
Antonio Passaro describes the long-lasting scientific and human legacy of his mentor, Filippo de Marinis, recipient of the #ELCC26 Heine H. Hansen Award, who sadly passed away in February. Read about de Marinis’ contributions in the #ESMODailyReporter 📌https://ow.ly/hpuI50YyAOn
2
0
0
0
#ELCC26 is underway in Copenhagen.
We’re at stand D352 - come & say hi 👋
We’re talking mental health, lived experience, & what needs to change in #lungcancer care across Europe.
It’s not too late to get a ticket to our 11th Report Launch on Thurs eve www.tickettailor.com/events/lungc...
#LCSM
5
0
0
0
Prof. Nicolas Girard joins COR2ED at the European Lung Cancer Congress, #ELCC26 , to share his highlights on oncogene-addicted NSCLC data from key trials, like Beamion LUNG-1, SOHO-01, OptiTROP-Lung03, and more.
Visit the COR2ED website to see the video & slides
cor2ed.com/elcc-2026
0
0
0
0